Article info

Download PDFPDF

1201 SGN-BB228 is a first-in-class CD228-targeted costimulatory antibody anticalin® bispecific delivering potent and conditional 4–1BB costimulation to tumor-specific T cells
Free

Authors

Citation

Heiser R
1201 SGN-BB228 is a first-in-class CD228-targeted costimulatory antibody anticalin® bispecific delivering potent and conditional 4–1BB costimulation to tumor-specific T cells

Publication history

  • First published November 7, 2022.
Online issue publication 
November 07, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.